ReviewFrontiers in cellular and infection microbiology2020
TIGIT Blockade: A Multipronged Approach to Target the HIV Reservoir.
Review in Frontiers in cellular and infection microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Impaired natural killer cell migration in HIV-infected individuals is caused by TIGIT-mediated inhibition of HIF-1α-dependent glycolysis.Cell death & disease · 2025Article
- Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection.Molecular therapy. Methods & clinical development · 2025Article
- TIGIT blockade improves anti-Mycobacterium tuberculosis immunity.PLoS pathogens · 2025Article
- Negative Immune Checkpoint Inhibitors.Pharmaceutics · 2025Review
- Limited restoration of T cell subset distribution and immune function in older people living with HIV-1 receiving HAART.Immunity & ageing : I & A · 2025Article
- Enhancement of Human Immunodeficiency Virus-Specific CD8Pathogens (Basel, Switzerland) · 2024Article
- PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma.Cancers · 2023Article
- HIV-1 Nef-mediated downregulation of CD155 results in viral restriction by KIR2DL5+ NK cells.PLoS pathogens · 2022Article
- Immune checkpoint blockade in HIV.EBioMedicine · 2022Review
- Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions.Frontiers in immunology · 2022Review
- Lung Cancer Induces NK Cell Contractility and Cytotoxicity Through Transcription Factor Nuclear Localization.Frontiers in cell and developmental biology · 2022Article
- Tissue-specific transcriptional profiling of plasmacytoid dendritic cells reveals a hyperactivated state in chronic SIV infection.PLoS pathogens · 2021Article
- Bringing Gene Therapies for HIV Disease to Resource-Limited Parts of the World.Human gene therapy · 2021Article
- TIGIT blockade enhances NK cell activity against autologous HIV-1-infected CD4Clinical & translational immunology · 2021Article
- Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma.Nature communications · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
During chronic human immunodeficiency virus type 1 (HIV-1) infection, upregulation of inhibitory molecules contributes to effector cell dysfunction and exhaustion. This, in combination with the ability of HIV-1 to reside dormant in cellular reservoirs and escape immune recognition, makes the pathway to HIV-1 cure particularly challenging. An idealized strategy to achieve HIV-1 cure proposes combined viral and immune activation by "shock"ing HIV-1 out of latency and into an immunologically visible state to be recognized and "kill"ed by immune effector cells. Here we outline the potential for blockade of the inhibitory immune checkpoint T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) to overcome natural killer (NK) cell and T cell inhibition associated with HIV-1 infection and invigorate antiviral effector cell responses against HIV-1 reactivated from the latent cellular reservoir.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.